ArticleCell reports2015
Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors.
Article in Cell reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine.Cellular oncology (Dordrecht, Netherlands) · 2025Pooled it
- SpatialFinder: a human-in-the-loop vision-language framework for prioritizing high-value regions in spatial transcriptomics.Frontiers in bioinformatics · 2026Article
- Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation.Nature cancer · 2025Article
- Establishment of nasal and olfactory epithelium organoids for unveiling mechanism of tissue regeneration and pathogenesis of nasal diseases.Cellular and molecular life sciences : CMLS · 2025Review
- Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.International journal of molecular sciences · 2024Review
- Prostate organoids: emerging experimental tools for translational research.The Journal of clinical investigation · 2023Review
- Article
- Innate Immune Program in Formation of Tumor-Initiating Cells from Cells-of-Origin of Breast, Prostate, and Ovarian Cancers.Cancers · 2023Review
- Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen.Endocrine-related cancer · 2022Article
- Urological cancer organoids, patients' avatars for precision medicine: past, present and future.Cell & bioscience · 2022Review
- Transcriptomic Signature and Growth Factor Regulation of Castration-Tolerant Prostate Luminal Progenitor Cells.Cancers · 2022Article
- Prostate cancer cell heterogeneity and plasticity: Insights from studies of genetically-engineered mouse models.Seminars in cancer biology · 2022Review
- Prostate luminal progenitor cells: from mouse to human, from health to disease.Nature reviews. Urology · 2022Review
- Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids.International journal of molecular sciences · 2022Article
- Establishment and characterization of prostate organoids from treatment-naïve patients with prostate cancer.Oncology letters · 2022Article
- Evolutionary selection of alleles in the melanophilin gene that impacts on prostate organ function and cancer risk.Evolution, medicine, and public health · 2021Article
- Developing Sustainable Classification of Diseases via Deep Learning and Semi-Supervised Learning.Healthcare (Basel, Switzerland) · 2020Article
- Protein Expression Analysis of an In Vitro Murine Model of Prostate Cancer Progression: Towards Identification of High-Potential Therapeutic Targets.Journal of personalized medicine · 2020Article
- Zebrafish Xenografts for Drug Discovery and Personalized Medicine.Trends in cancer · 2020Review
- Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer.The Journal of experimental medicine · 2020Article
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
Primary prostate cancer almost always has a luminal phenotype. However, little is known about the stem/progenitor properties of transformed cells within tumors. Using the aggressive Pten/Tp53-null mouse model of prostate cancer, we show that two classes of luminal progenitors exist within a tumor. Not only did tumors contain previously described multipotent progenitors, but also a major population of committed luminal progenitors. Luminal cells, sorted directly from tumors or grown as organoids, initiated tumors of adenocarcinoma or multilineage histological phenotypes, which is consistent with luminal and multipotent differentiation potentials, respectively. Moreover, using organoids we show that the ability of luminal-committed progenitors to self-renew is a tumor-specific property, absent in benign luminal cells. Finally, a significant fraction of luminal progenitors survived in vivo castration. In all, these data reveal two luminal tumor populations with different stem/progenitor cell capacities, providing insight into prostate cancer cells that initiate tumors and can influence treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.